Business
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n Data demonstrated very high correlation with PCR ct values in positive patients Data demonstrated 100% sensitivity, as early as 1-3 days post-exposure, in identifying fully vaccinated asymptomatic patients infected with COVID-19 New York, NY, and Tel Aviv, ISRAEL, Oct. 06, 2021 (GLOBE NEWSWIRE) --  via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its joint venture partner NLC Pharma, today announced positive clinical validation data for its 3CL protease biomarker assay TolloTest™ in a clinical study evaluating its sensitivity compared with PCR in hospitalized COVID-19 patients, patients hospitalized for conditions other than COVID-19 and individuals exposed to confirmed COVID-19 subjects in the community outpatient setting and healthy controls. The results clinically validated the sensitivity of the 3CL protease biomarker compared with SARS-CoV-2 PCR confirmed positive results in both the hospital and outpatient setting, and provided key insights on the potential role the 3CL protease biomarker could play in assessing the COVID infectivity status of infected patients being released from quarantine and opening the diagnostic window to include earlier diagnosis of individuals from time of time known exposure. The Company sees multiple use cases for the 3CL protease biomarker as an adjunct to both PCR testing and antigen testing for SARS-CoV-2. The 3CL protease is the main protease found in coronaviruses.  When a cell becomes infected with the virus, one of the first viral components made is the 3CL protease, which is an enzymatic saw that cleaves coronavirus polypeptides into usable viral proteins.  Since a healthy human body doesn’t contain any traces of 3CL protease it’s an ideal biomarker that will show up only if there is active infection.  In theory a 3CL protease test is a much better test for pandemic management because it could identify patients who are capable of spreading the disease and help them. “We believe that the 3CL protease could become a very important biomarker in the overall COVID-19 diagnostic landscape,” said Jorge Leon, PhD, Chief Scientific Officer at Todos Medical. “To date, the only questions that the widely used PCR and...